BIO
Income statement / Annual
Last year (2024), Bio-Rad Laboratories, Inc.'s total revenue was $2.57 B,
a decrease of 3.92% from the previous year.
In 2024, Bio-Rad Laboratories, Inc.'s net income was -$1.84 B.
See Bio-Rad Laboratories, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$2.57 B |
$2.67 B |
$2.80 B |
$2.92 B |
$2.55 B |
$2.31 B |
$2.29 B |
$2.16 B |
$2.07 B |
$2.02 B |
Cost of Revenue |
$1.19 B
|
$1.24 B
|
$1.23 B
|
$1.28 B
|
$1.11 B
|
$1.05 B
|
$1.07 B
|
$972.75 M
|
$930.09 M
|
$897.77 M
|
Gross Profit |
$1.38 B
|
$1.43 B
|
$1.57 B
|
$1.64 B
|
$1.44 B
|
$1.26 B
|
$1.22 B
|
$1.19 B
|
$1.14 B
|
$1.12 B
|
Gross Profit Ratio |
0.54
|
0.53
|
0.56
|
0.56
|
0.56
|
0.54
|
0.53
|
0.55
|
0.55
|
0.56
|
Research and Development Expenses |
$295.90 M
|
$247.43 M
|
$256.89 M
|
$271.66 M
|
$226.60 M
|
$202.71 M
|
$199.20 M
|
$250.30 M
|
$205.86 M
|
$192.97 M
|
General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$834.78 M
|
$808.94 M
|
$816.72 M
|
$761.99 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.49 M
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$814.00 M
|
$824.22 M
|
$827.83 M
|
$879.57 M
|
$800.27 M
|
$824.63 M
|
$833.29 M
|
$808.94 M
|
$816.72 M
|
$761.99 M
|
Other Expenses |
$0.00
|
$0.00
|
$44.57 M
|
$26.78 M
|
$24.49 M
|
$26.09 M
|
$36.59 M
|
$12.20 M
|
$14.85 M
|
$11.08 M
|
Operating Expenses |
$1.11 B
|
$1.05 B
|
$1.08 B
|
$1.15 B
|
$1.03 B
|
$1.03 B
|
$1.03 B
|
$1.06 B
|
$1.02 B
|
$954.96 M
|
Cost And Expenses |
$2.30 B
|
$2.29 B
|
$2.32 B
|
$2.43 B
|
$2.13 B
|
$2.08 B
|
$2.10 B
|
$2.03 B
|
$1.95 B
|
$1.85 B
|
Interest Income |
$82.00 M
|
$100.90 M
|
$58.00 M
|
$18.90 M
|
$18.20 M
|
$30.50 M
|
$26.60 M
|
$19.10 M
|
$14.70 M
|
$10.10 M
|
Interest Expense |
$48.90 M
|
$49.44 M
|
$38.11 M
|
$1.55 M
|
$21.86 M
|
$23.42 M
|
$23.96 M
|
$21.91 M
|
$21.94 M
|
$21.69 M
|
Depreciation & Amortization |
$151.60 M
|
$145.90 M
|
$177.20 M
|
$176.90 M
|
$175.20 M
|
$174.50 M
|
$138.10 M
|
$148.70 M
|
$142.90 M
|
$131.85 M
|
EBITDA |
-$2.14 B |
-$608.26 M |
-$4.49 B |
$5.63 B |
$5.10 B |
$2.46 B |
$674.72 M |
$269.52 M |
$206.40 M |
$299.34 M |
EBITDA Ratio |
-0.83
|
-0.23
|
0.24
|
0.22
|
0.23
|
0.17
|
0.16
|
0.13
|
0.13
|
0.15
|
Operating Income Ratio |
0.1
|
0.13
|
0.17
|
0.17
|
0.16
|
0.1
|
-0.05
|
0.05
|
0.03
|
0.08
|
Total Other Income/Expenses Net |
-$2.61 B
|
-$1.19 B
|
-$5.19 B
|
$4.95 B
|
$4.49 B
|
$2.03 B
|
$319.39 M
|
-$15.35 M
|
-$73.94 M
|
-$20.86 M
|
Income Before Tax |
-$2.34 B
|
-$850.10 M
|
-$4.70 B
|
$5.44 B
|
$4.91 B
|
$2.26 B
|
$507.36 M
|
$97.81 M
|
$41.56 M
|
$145.85 M
|
Income Before Tax Ratio |
-0.91
|
-0.32
|
-1.68
|
1.86
|
1.93
|
0.98
|
0.22
|
0.05
|
0.02
|
0.07
|
Income Tax Expense |
-$498.30 M
|
-$212.78 M
|
-$1.08 B
|
$1.19 B
|
$1.10 B
|
$502.41 M
|
$146.36 M
|
-$16.94 M
|
$13.44 M
|
$32.75 M
|
Net Income |
-$1.84 B
|
-$637.32 M
|
-$3.63 B
|
$4.25 B
|
$3.81 B
|
$1.76 B
|
$361.00 M
|
$114.74 M
|
$28.13 M
|
$113.09 M
|
Net Income Ratio |
-0.72
|
-0.24
|
-1.29
|
1.46
|
1.5
|
0.76
|
0.16
|
0.05
|
0.01
|
0.06
|
EPS |
-65.36 |
-21.82 |
-121.79 |
142.61 |
127.86 |
58.93 |
12.1 |
4.12 |
0.88 |
3.74 |
EPS Diluted |
-65.36 |
-21.82 |
-121.79 |
140.83 |
126.2 |
58.27 |
11.94 |
4.07 |
0.88 |
3.71 |
Weighted Average Shares Out |
$28.21 M
|
$29.21 M
|
$29.79 M
|
$29.83 M
|
$29.77 M
|
$29.84 M
|
$29.84 M
|
$29.66 M
|
$29.44 M
|
$29.19 M
|
Weighted Average Shares Out Diluted |
$28.21 M
|
$29.21 M
|
$29.79 M
|
$30.21 M
|
$30.16 M
|
$30.18 M
|
$30.23 M
|
$30.03 M
|
$29.65 M
|
$29.41 M
|
Link |
|
|
|
|
|
|
|
|
|
|